Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer

Yang, Jeongmo; Pyo, Jung‐Soo; Kang, Gyu-Hong

doi:10.1177/1724600818772194

Cited by 9 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings confirm that EGFR mutations are the predominant detectable alteration, with a prevalence rate consistent with previous studies in East Asian patients [14]. Furthermore, rates of ALK and ROS1 rearrangements are also similar [15,16].…”

Section: Discussionsupporting

confidence: 90%

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

et al. 2020

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

et al. 2020

View full text Add to dashboard Cite

“…1 Epidemiological data indicates that ROS1 gene rearrangement occurs in approximately 1%-2% of NSCLC patients. 14 This contradicts the fact that our patient has smoked for a long time, but the overexpression of ROS1 rather than TP53 or NRAS may be a plausible explanation for the early success of the patient's chemotherapy, antiangiogenic therapy, and targeted therapy. Previous research suggested that TTF-1 and Napsin A, both of which had a sensitivity of about 80% and were more easily evaluated as a nuclear stain, were well-established markers for the identification of adenocarcinoma differentiation.…”

Section: Bdg Test Negative T-lymphocyte Subsets (Flow Cytometry) Normalmentioning

confidence: 56%

“…In NSCLC, KRAS mutations, especially transversion mutations, were often found in smokers, while EGFR , ALK , ROS1 , and RET mutations or translocations might be more common in light smokers or non‐smokers, other alterations such as TP53 , NRAS , and MAP2K1 are also more common in smokers 1 . Epidemiological data indicates that ROS1 gene rearrangement occurs in approximately 1%–2% of NSCLC patients 14 . This contradicts the fact that our patient has smoked for a long time, but the overexpression of ROS1 rather than TP53 or NRAS may be a plausible explanation for the early success of the patient's chemotherapy, antiangiogenic therapy, and targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report

Sun

Wang

Shi

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical Message In conclusion author highlights the tumor cell genetic testing or molecular pathological diagnosis plays a key role in the individualized treatment of PSC, which could benefit patients with advanced PSC. Abstract An uncommon form of non‐small‐cell lung cancer (NSCLC) with a poor prognosis is pulmonary sarcomatoid carcinoma (PSC). Surgical resection is currently the preferred treatment, but guidelines for adjuvant chemotherapy have not yet been established, especially for the advanced stage. The development of molecular subgroups in the field of tumors may be advantageous to advanced PSC patients with the ongoing progress of genomics and immunology. A 54‐year‐old man presented to Xishan People's Hospital of Wuxi City with recurrent intermittent dry cough with fever for 1 month. Further examinations suggested the diagnosis of PSC occupying almost the entire right interlobar fissure area combined with malignant pleural effusion (Stage IVa). Pathological examination confirmed the diagnosis of PSC with ROS1 overexpressing via genetic testing. However, after three cycles of chemo‐, antiangiogenetic‐ and immunochemical therapy, the lesion was localized, and pleural effusion disappeared, the patient subsequently received an operation which was performed as R0 resection. Unfortunately, the patient became deteriorated quickly followed by extensive metastatic nodules in the thoracic cavity. Although the patient continued to receive chemo‐ and immunochemical‐therapy, it did not limit the progress of the tumor, leading to widespread metastasis, and eventually died of multiple organ failure. For PSC patients with Stage IVa, chemo‐, antiangiogenetic‐ and immunochemical‐therapy performs well in clinical efficacy, and comprehensive panel‐based genetic testing may offer PSC patients a somewhat better prognosis. However, blindly implementing surgical treatment may bring harm to the patient and affect long‐term survival. It's essential to know the surgical indications precisely by NSCLC guidelines.

show abstract

“…In comparison, the proportion of ROS1 -rearranged non-adenocarcinoma patients in this study was 1.37%. The incidence of ROS1 gene rearrangement is higher in adenosquamous carcinoma and pleomorphic carcinoma than adenocarcinoma, which is one of the reasons for the higher rate ( 62 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis

Bi¹,

Ding²,

Yin³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background ROS1 gene rearrangement has been reported in several types of cancers, including non-small cell lung cancer (NSCLC). It is reported that tyrosine kinase inhibitors are effective in the treatment of ROS1- rearranged NSCLC. Therefore, the identification of ROS1 rearrangement can be used as potential therapeutic target in lung cancer. Epidemiological data indicates that ROS1 gene rearrangement occurs in approximately 1–2% of NSCLC patients. The small sample sizes of the existing associated studies only represent the characteristics of patients in specific regions or countries, and there is still no latest statistical analysis on ROS1 gene rearrangement anywhere in the world. Methods We conducted a systematic search of the PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), CBM, CNKI, Wanfang, and VIP databases to identify studies on ROS1 gene rearrangement in NSCLC patients from January 1, 2015 to October 27, 2019. We conducted a meta-analysis to investigate the relationship between ROS1 gene rearrangement and clinical characteristics of NSCLC patients. The four clinical features are as follows: gender, smoking status, pathological type, and lung cancer stage. Results Thirty-nine studies constituting of 25,055 NSCLC patients were eligible for inclusion in this meta-analysis. A prominently higher rate of ROS1 gene rearrangement was observed in female NSCLC patients (OR =1.94, 95% CI: 1.62–2.32%, P<0.05), patients with no smoking history (OR =2.82, 95% CI: 2.24–3.55%, P<0.05), patients with adenocarcinoma (OR =1.55, 95% CI: 1.14–2.11%, P<0.05), and patients with stage III–IV disease (OR =1.50, 95% CI: 1.15–1.94%, P<0.05). Our meta-analysis also showed that the prevalence of ROS1 rearrangement in adenocarcinoma was 2.49% (95% CI: 1.92–3.11%), while it was lower in non-adenocarcinoma patients (1.37%). Conclusions ROS1 gene rearrangement was more predominant in female patients, patients without smoking history, patients with adenocarcinoma and patients with advanced-stage disease (stages III to IV).

show abstract

Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer

Abstract: The rates of ROS1 rearrangement differed by tumor histologic subtype in NSCLC. ROS1 IHC may be useful for the detection of ROS1 rearrangement in NSCLC. Detailed criteria for evaluating ROS1 IHC are needed before it can be applied in daily practice.

Cited by 9 publications

References 47 publications

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis

Comprehensive treatment for ROS1‐overexpressed pulmonary sarcomatoid carcinoma: A case report

Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis

Contact Info

Product

Resources

About